| Project Name | Therapeuticarea | Target/MOA | Expected registration category | Mono/Combo | Intended Indications | Pre-Clinical | IND | PhaseI | PhaseII | PhaseIII | NDA |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C019199 | Oncology | CSF-1R/DDR1/VEGFR2 Immuno- oncology therapy | Class l chemical drugs | Mono | Osteosarcoma |
CN
US
|
|||||
| HER2- breast cancer |
CN
|
||||||||||
| Tenosynovial giant cell tumor (TGCT) |
CN
|
||||||||||
| Melanoma |
CN
|
||||||||||
| Combo(anti-PD-1mAbs) | Triple-negative breast cancer(TNBC) |
CN
US
|
|||||||||
| Colorectal cancer (CRC) |
CN
|
||||||||||
| Pancreatic cancer |
CN
|
||||||||||
| Gastric cancer |
CN
|
||||||||||
| Esophageal squamouscell carcinoma |
CN
|
||||||||||
| Head and neck squamous cell carcinoma |
CN
|
||||||||||
| HXP056 | Ophthalmology | VEGFR2 | Class l chemical drugs | Mono | Wet age-related macular degeneration:(wAMD) |
CN
|
|||||
| Diabetic macular edema (DME) |
CN
|
||||||||||
| Retinal veinocclusion(RVO) |
CN
|
Fujian Haixi New Pharmaceutical Creation Co., Ltd. Fujian ICP Record No. 12015727 Internet Drug Information Service Qualification Certificate No.: (Min) - Non-operating-2023-0063
Some of the text and pictures on this site are from the Internet and are only used for sharing and learning. If your rights and interests are infringed, please inform us in time, and this site will deal with or replace them in time.
